Previous 10 | Next 10 |
2023-11-27 21:17:36 ET Summary Al Gore's 13F portfolio value decreased by 8% to $19B, with 43 positions. Top five stakes are Microsoft, Amazon.com, Applied Materials, Henry Schein, and Thermo Fisher Scientific. New stake in Trimble Inc., stake disposal in PTC Inc., stake incre...
2023-11-22 07:17:09 ET More on the markets SPY: Sell The Rally - Historical Patterns Show Misplaced Optimism S&P 500: Forget The Year-End Rally The Message From 12 Post-CPI Charts Chart Talk: S&P 500 hasn’t hit an all-time high in 471 days, sev...
2023-11-16 17:16:46 ET More on Henry Schein Henry Schein: Economic Value Matches Market-Implied Expectations, Reiterate Hold Henry Schein Non-GAAP EPS of $1.32 in-line, revenue of $3.16B misses by $50M For further details see: Henry Schein announces receipt of de...
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announces that it received an expected notice (the “Notice”) on November 13, 2023 from the Listing Qualifications Department of The Nasda...
2023-11-13 12:40:00 ET Summary An impressive winning streak on the three major indices came to an end late last week as fears of sustained higher interest rates hit markets. This week, 1,410 companies are expected to report for Q3, 12 from the S&P 500®. All eyes will ...
Stocks rose on Monday, as traders tried to move past Moody's Investors Service lowering its U.S. credit rating outlook to negative from stable. The Dow Jones Industrials regained 93.85 points to 34,376.95. The S&P 50 index fell 0.12 points to 4,415.12. The NASDAQ slid 27.15 points...
2023-11-13 06:05:34 ET More on Henry Schein Henry Schein: Economic Value Matches Market-Implied Expectations, Reiterate Hold Henry Schein Q3 2023 Earnings Preview Henry Schein upgraded at Stifel ahead of Q3 earnings Seeking Alpha’s Quant Rating on Henr...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
GAAP diluted EPS of $1.05 and non-GAAP diluted EPS of $1.32, reflecting stable net total sales growth of 3.1% 2023 non-GAAP diluted EPS guidance of $4.43 to $4.71 updated to reflect: a narrowing of previous guidance to $5.18 to $5.26 from $5.18 to $5.35 due to softening macroecono...
Henry Schein Inc. (HSIC) is expected to report $1.33 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:00:09 ET Jeff Johnson from Robert W. Baird issued a price target of $92.00 for HSIC on 2024-07-22 03:31:00. The adjusted price target was set to $92.00. At the time of the announcement, HSIC was trading at $70.34. The overall price target consensus is at $8...
Facility Designed To Improve Efficiency, Enable Innovation, and Better Serve Customers; Modernized, 811K Square Foot Facility in Fort Worth Largest in the Company’s Network Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office...
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2024 financial results before the stock market opens on Tuesday, August 6, 2024, and will provi...